Notch is out — your watchlist beside the MacBook notch, synced with this account.
Learn more ↗We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
HLB is a company engaged in the biotechnology and pharmaceutical sectors. Its primary focus is on the development and commercialization of new anticancer drugs, with the oral targeted anticancer drug 'Riboceranib' serving as its core pipeline asset. Additionally, it also has a medical device manufacturing and sales segment.
HLB는 생명공학 및 제약 사업을 영위하는 기업입니다. 주요 사업은 항암 신약 개발 및 상업화에 중점을 두고 있으며, 경구용 표적 항암제 '리보세라닙'이 핵심 파이프라인입니다. 또한, 의료기기 제조 및 판매 사업도 일부 영위하고 있습니다.
